These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 2997488)

  • 41. Effects of acute oral sodium potassium citrate load in healthy males--outlook for treatment of patients with calcium-containing renal stones.
    Schwille PO; Rümenapf G; Köhler R; Sörgel F
    Urol Int; 1987; 42(2):81-8. PubMed ID: 3617247
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Influence of urine pH and citrate concentration on the upper limit of metastability for calcium phosphate.
    Greischar A; Nakagawa Y; Coe FL
    J Urol; 2003 Mar; 169(3):867-70. PubMed ID: 12576801
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Alkaline citrate in prevention of recurrent calcium oxalate stones.
    Berg C
    Scand J Urol Nephrol Suppl; 1990; 130():1-83. PubMed ID: 2291093
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Juvenile renal stone disease: a study of urinary promoting and inhibiting factors.
    Baggio B; Gambaro G; Favaro S; Borsatti A; Pavanello L; Siviero B; Zacchello G; Rizzoni GF
    J Urol; 1983 Dec; 130(6):1133-5. PubMed ID: 6315967
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of factors involved in calcium stone formation.
    Abraham PA; Smith CL
    Miner Electrolyte Metab; 1987; 13(3):201-8. PubMed ID: 3627051
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of magnesium oxide on the crystallization of calcium salts in urine in patients with recurrent nephrolithiasis.
    Fetner CD; Barilla DE; Townsend J; Pak CY
    J Urol; 1978 Oct; 120(4):399-401. PubMed ID: 702659
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effect of some urinary stone inhibitors on membrane interaction potentials of stone crystals.
    Mandel NS; Mandel GS; Hasegawa AT
    J Urol; 1987 Sep; 138(3):557-62. PubMed ID: 2442419
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of monofluorophosphate on calcium phosphate formation in supersaturated solutions.
    Vintiner GM; Pearce EI
    Caries Res; 1990; 24(2):101-6. PubMed ID: 2160326
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of meal on the physiological and physicochemical actions of potassium citrate.
    Pak CY; Oh MS; Baker S; Morris JS
    J Urol; 1991 Sep; 146(3):803-5. PubMed ID: 1875495
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Renal stone.
    Modlin M
    Br J Clin Pract; 1968 Dec; 22(12):531-5. PubMed ID: 4302529
    [No Abstract]   [Full Text] [Related]  

  • 51. The effect of gallium on seeded hydroxyapatite growth.
    Donnelly R; Boskey A
    Calcif Tissue Int; 1989 Feb; 44(2):138-42. PubMed ID: 2537134
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interaction of citric acid with hydroxyapatite: surface exchange of ions and precipitation of calcium citrate.
    Misra DN
    J Dent Res; 1996 Jun; 75(6):1418-25. PubMed ID: 8831638
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Influence of chondroitin sulfate, heparin sulfate, and citrate on Proteus mirabilis-induced struvite crystallization in vitro.
    McLean RJ; Downey J; Clapham L; Nickel JC
    J Urol; 1990 Nov; 144(5):1267-71. PubMed ID: 2122009
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Risk indicators of urinary calculus formation: value of oxalate and citrate excretion in comparison with the oxalate tolerance value].
    Hannak D; Burczyk U; Bartelt U; Kattermann R
    Urologe A; 1989 Jan; 28(1):20-4. PubMed ID: 2922896
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Experimental studies on the effect of inhibitors of crystallization in the urine].
    Berg W; Börner RH
    Z Urol Nephrol; 1979 May; 72(5):383-90. PubMed ID: 225904
    [No Abstract]   [Full Text] [Related]  

  • 56. Effectiveness of phosphocitrate and N-sulpho-2-amino tricarballylate, a new analogue of phosphocitrate, in blocking hydroxyapatite induced crystal growth and calcium accumulation by matrix vesicles.
    Shankar R; Brown MR; Wong LK; Sallis JD
    Experientia; 1984 Mar; 40(3):265-7. PubMed ID: 6321227
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effects of potassium and magnesium supplementations on urinary risk factors of renal stone patients.
    Jaipakdee S; Prasongwatana V; Premgamone A; Reungjui S; Tosukhowong P; Tungsanga K; Suwantrai S; Noppawinyoowong C; Maskasame S; Sriboonlue P
    J Med Assoc Thai; 2004 Mar; 87(3):255-63. PubMed ID: 15117041
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The effects of high-dose ascorbic acid administration on the factors of lithogenesis in the rat].
    Sakly R; Zarrouk K; Hedhili A; Achour A; Kallel Z; Mbazzaa A
    Ann Urol (Paris); 1991; 25(5):242-5. PubMed ID: 1663724
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Diurnal variations in calcium phosphate and calcium oxalate activity products in normal and stone-forming urines.
    Hodgkinson A; Marshall RW; Cochran M
    Isr J Med Sci; 1971 Nov; 7(11):1230-4. PubMed ID: 5159604
    [No Abstract]   [Full Text] [Related]  

  • 60. Isolation and identification of some urinary inhibitors of calcium phosphate formation.
    Sutor DJ; Percival JM; Doonan S
    Clin Chim Acta; 1978 Oct; 89(2):273-8. PubMed ID: 213213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.